137 related articles for article (PubMed ID: 22553810)
1. Comparison of immunohistochemical staining in breast papillary neoplasms of cytokeratin 5/6 and p63 in core needle biopsies and surgical excisions.
Koo JS; Kim MJ; Kim EK; Park BW
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):108-15. PubMed ID: 22553810
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens.
Shah VI; Flowers CI; Douglas-Jones AG; Dallimore NS; Rashid M
Histopathology; 2006 May; 48(6):683-91. PubMed ID: 16681684
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
4. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of Papillary Breast Lesions on Core Needle Biopsy: Upgrade Rates and Interobserver Variability.
Qiu L; Mais DD; Nicolas M; Nanyes J; Kist K; Nazarullah A
Int J Surg Pathol; 2019 Oct; 27(7):736-743. PubMed ID: 31187678
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
7. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
8. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
Masood S; Loya A; Khalbuss W
Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
[TBL] [Abstract][Full Text] [Related]
9. The significance of combined CK5/6 and p63 immunohistochemistry in predicting the risks of subsequent carcinoma development in intraductal papilloma of the breast.
Yang Y; Suzuki K; Abe E; Li C; Uno M; Akiyama F; Yamauchi H; Kikuchi M; Ohde S; Deshpande G; Shibahara Y; Nakamura Y; Sasano H
Pathol Int; 2015 Feb; 65(2):81-8. PubMed ID: 25572436
[TBL] [Abstract][Full Text] [Related]
10. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
Ding Y; Ruan Q
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):405-7. PubMed ID: 17120733
[TBL] [Abstract][Full Text] [Related]
11. Histological evaluation of papillary lesions of the breast from needle biopsy to the excised specimen: a single institutional experience.
Gilani S; Tashjian R; Kowalski P
Pathologica; 2013 Apr; 105(2):51-5. PubMed ID: 23946981
[TBL] [Abstract][Full Text] [Related]
12. Management of papillary breast lesions diagnosed on core-needle biopsy: clinical pathologic and radiologic analysis of 276 cases with surgical follow-up.
Rizzo M; Linebarger J; Lowe MC; Pan L; Gabram SG; Vasquez L; Cohen MA; Mosunjac M
J Am Coll Surg; 2012 Mar; 214(3):280-7. PubMed ID: 22244207
[TBL] [Abstract][Full Text] [Related]
13. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
14. Papillary lesions of the breast at percutaneous core-needle biopsy.
Mercado CL; Hamele-Bena D; Oken SM; Singer CI; Cangiarella J
Radiology; 2006 Mar; 238(3):801-8. PubMed ID: 16424237
[TBL] [Abstract][Full Text] [Related]
15. Significance of papillary lesions at percutaneous breast biopsy.
Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A
Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908
[TBL] [Abstract][Full Text] [Related]
16. Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction.
Reisenbichler ES; Balmer NN; Adams AL; Pfeifer JD; Hameed O
Mod Pathol; 2011 Feb; 24(2):185-93. PubMed ID: 21076459
[TBL] [Abstract][Full Text] [Related]
17. Well-differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63.
Panse G; Cowper SE; Leffell DJ; Pulitzer M; Ko CJ
J Cutan Pathol; 2017 Jun; 44(6):557-562. PubMed ID: 28417484
[TBL] [Abstract][Full Text] [Related]
18. Papillary lesions of the breast diagnosed by core needle biopsy: 71 cases with surgical follow-up.
Bernik SF; Troob S; Ying BL; Simpson SA; Axelrod DM; Siegel B; Moncrief RM; Mills C; Aziz M
Am J Surg; 2009 Apr; 197(4):473-8. PubMed ID: 18723154
[TBL] [Abstract][Full Text] [Related]
19. Can additional immunohistochemistry staining replace the surgical excision for the diagnosis of papillary breast lesions classified as benign on 14-gage core needle biopsy?
Koo JS; Han K; Kim MJ; Moon HJ; Kim EK; Park BW
Breast Cancer Res Treat; 2013 Feb; 137(3):797-806. PubMed ID: 23292118
[TBL] [Abstract][Full Text] [Related]
20. Imaging-guided core needle biopsy of papillary lesions of the breast.
Rosen EL; Bentley RC; Baker JA; Soo MS
AJR Am J Roentgenol; 2002 Nov; 179(5):1185-92. PubMed ID: 12388496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
